Cargando…

Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration

BACKGROUND AND OBJECTIVES: Inhibition of Abelson (Abl) tyrosine kinase as a therapeutic target has been gaining attention in neurodegeneration. Post-mortem Alzheimer’s and Parkinson’s disease brains show that the levels of several other tyrosine kinases, including Discoidin Domain Receptors (DDR1/2)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fowler, Alan J., Hebron, Michaeline, Missner, Alexander A., Wang, Ruchong, Gao, Xiaokong, Kurd-Misto, Bahjat T., Liu, Xiaoguang, Moussa, Charbel E.-H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544596/ https://www.ncbi.nlm.nih.gov/pubmed/30919310 http://dx.doi.org/10.1007/s40268-019-0266-z

Ejemplares similares

Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration
por: Hebron, Michaeline, et al.
Publicado: (2015)

Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease
por: Stevenson, Max, et al.
Publicado: (2023)

Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance
por: Lonskaya, Irina, et al.
Publicado: (2013)

Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy
por: Hebron, Michaeline L., et al.
Publicado: (2014)

Inhibition of Ubiquitin-Specific Protease-13 Improves Behavioral Performance in Alpha-Synuclein Expressing Mice
por: Liu, Xiaoguang, et al.
Publicado: (2022)

Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling
por: Bieerkehazhi, Shayahati, et al.
Publicado: (2016)

Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology
por: Liu, Xiaoguang, et al.
Publicado: (2021)

Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models
por: Lonskaya, Irina, et al.
Publicado: (2014)

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial
por: Pagan, Fernando. L., et al.
Publicado: (2020)

Ubiquitination Increases Parkin Activity to Promote Autophagic α-Synuclein Clearance
por: Lonskaya, Irina, et al.
Publicado: (2013)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
por: Lin, Tong, et al.
Publicado: (2017)

Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases
por: Desforges, Nicole M., et al.
Publicado: (2012)

Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib
por: Pan, Hongming, et al.
Publicado: (2014)

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease
por: Moussa, Charbel, et al.
Publicado: (2017)

DDR1 promotes E-cadherin stability via inhibition of integrin-β1-Src activation-mediated E-cadherin endocytosis
por: Chen, Hong-Ru, et al.
Publicado: (2016)

4564 Nilotinib alters microRNAs that regulate specific autophagy and ubiquitination genes in the cerebrospinal fluid of Parkinson’s patients
por: Fowler, Alan, et al.
Publicado: (2020)

A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
por: Levinson, Nicholas M, et al.
Publicado: (2006)

CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease
por: Fowler, Alan J., et al.
Publicado: (2021)

Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma
por: Takigawa, Hidehiko, et al.
Publicado: (2016)

CD133 Is Associated with Increased Melanoma Cell Survival after Multikinase Inhibition
por: Simbulan-Rosenthal, Cynthia M., et al.
Publicado: (2019)

Author Correction: Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib
por: Pan, Hongming, et al.
Publicado: (2020)

Src and Abl hijack the Robo1 pathway
por: Naus, Christian
Publicado: (2010)

Abl Is Able to Inhibit Cell Engulfment
por: Robinson, Richard
Publicado: (2009)

Cbl-associated protein is tyrosine phosphorylated by c-Abl and c-Src kinases
por: Fernow, Inga, et al.
Publicado: (2009)

Roles for c-Abl in postoperative neurodegeneration
por: Feng, Long, et al.
Publicado: (2022)

Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease
por: Pagan, Fernando L., et al.
Publicado: (2020)

DDR1 inhibition as a new therapeutic strategy for colorectal cancer
por: Sirvent, Audrey, et al.
Publicado: (2018)

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
por: Rassi, Fuad El, et al.
Publicado: (2013)

Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies
por: Pagan, Fernando L., et al.
Publicado: (2022)

Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer
por: Wirth, Lori J., et al.
Publicado: (2019)

Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease Patients
por: Anderson, Karen E., et al.
Publicado: (2022)

SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia
por: Sarno, Jolanda, et al.
Publicado: (2018)

Computational Study of the “DFG-Flip” Conformational Transition in c-Abl and c-Src Tyrosine Kinases
por: Meng, Yilin, et al.
Publicado: (2014)

Src- and Abl-family kinases activate spleen tyrosine kinase to maximize phagocytosis and Leishmania infection
por: Ullah, Imran, et al.
Publicado: (2023)

Antiproliferative Activity, Multikinase Inhibition, Apoptosis- Inducing Effects and Molecular Docking of Novel Isatin–Purine Hybrids
por: Alanazi, Ashwag S., et al.
Publicado: (2023)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018)

KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy
por: Ambrogio, Chiara, et al.
Publicado: (2016)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Inositol polyphosphate multikinase signaling in the regulation of metabolism
por: Lee, Joo-Young, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5s6nbjqfauccp41v70ruqadnhh